S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Fund/Baker Bros Advisors/Q3 2020

Baker Bros Advisors

Periodo: Q3 2020 Β· Depositato: 2020-11-16
Vedi su SEC EDGAR β†—
AUM
$25.03B
Valore totale del portafoglio
Posizioni
120
Titoli dichiarati
Prima Posizione
SGEN
37.0% $9.25B
Var. Trimestrali
+8 / -8
nuovi Β· usciti
⚠️Informativa sui Depositi 13F

I dati AUM mostrati sono calcolati sommando il valore di mercato dichiarato di tutte le posizioni nei depositi SEC 13F-HR β€” non rappresentano il patrimonio effettivo gestito dal fondo.

  • Escluse liquiditΓ , obbligazioni, private equity, posizioni corte e azioni estere non soggette all'obbligo di dichiarazione.
  • Per le opzioni PUT e CALL, il Valore dichiarato Γ¨ il valore nozionale delle azioni sottostanti β€” non il premio pagato. CiΓ² sovrastima significativamente il capitale effettivamente a rischio.
  • Il patrimonio reale del fondo Γ¨ tipicamente superiore e include strategie, strumenti e posizioni che non compaiono mai in un 13F.
  • I depositi 13F riguardano i gestori istituzionali con β‰₯$100M in titoli 13F. Le posizioni riflettono le partecipazioni a fine trimestre, divulgate entro 45 giorni dalla fine del periodo.

Dati provenienti da SEC EDGAR. Questo tracker Γ¨ a scopo puramente informativo e non costituisce consulenza finanziaria.

Partecipazioni in Portafoglio

Prime 30 posizioni

⚠️ Performance % calcolata dalla data di deposito ( 2020-11-16) si riferisce al titolo sottostante β€” non al P&L del derivato.
TickerEmittenteNozionalePortafoglio %Al DepositoOra (Fine Giornata)Dal DepositoAllocazione
SGENSeagen Inc.$9.25B36.96%β€”β€”
37.0%
ONCBeiGene, Ltd.$3.81B15.22%$286.44$297.65+3.9%
15.2%
INCYIncyte Corporation$2.87B11.47%$89.74$116.86+30.2%
11.5%
ACADACADIA Pharmaceuticals Inc.$1.73B6.91%$41.25$25.97-37.0%
6.9%
ALXNAlexion Pharmaceuticals, Inc.$1.00B4.01%β€”β€”
4.0%
KODKodiak Sciences Inc.$731.4M2.92%$59.21$38.54-34.9%
2.9%
BMRNBioMarin Pharmaceutical Inc.$577.4M2.31%$76.08$58.99-22.5%
2.3%
ASNDAscendis Pharma A/S$546.3M2.18%$154.32$274.50+77.9%
2.2%
NVTAQInvitae Corporation$513.7M2.05%β€”β€”
2.0%
MYOKMyoKardia, Inc.$410.3M1.64%β€”β€”
1.6%
PRLDPrelude Therapeutics Incorporated$304.9M1.22%$30.13$4.91-83.7%
1.2%
ARGXargenx SE$267.6M1.07%$262.52$939.68+257.9%
1.1%
MRTXMirati Therapeutics, Inc.$234.1M0.94%β€”β€”
0.9%
IGMSIGM Biosciences, Inc.$232.1M0.93%β€”β€”
0.9%
EXASExact Sciences Corporation$188.2M0.75%β€”β€”
0.8%
MDGLMadrigal Pharmaceuticals, Inc.$178.0M0.71%$118.73$528.10+344.8%
0.7%
AMRNXXXXAmarin Corporation plc$134.8M0.54%β€”β€”
0.5%
HRTXHeron Therapeutics, Inc.$88.8M0.35%$14.82$0.44-97.0%
0.3%
FMTXForma Therapeutics Holdings, Inc.$88.3M0.35%β€”β€”
0.3%
CERSCerus Corporation$85.8M0.34%$6.26$3.16-49.5%
0.3%
ZYMEZymeworks Inc.$79.6M0.32%$46.58$26.31-43.5%
0.3%
INSMInsmed Incorporated$73.0M0.29%$32.14$111.60+247.2%
0.3%
AXSMAxsome Therapeutics, Inc.$68.4M0.27%$71.25$244.31+242.9%
0.3%
NBIXNeurocrine Biosciences, Inc.$65.1M0.26%$96.16$174.26+81.2%
0.3%
KYMRKymera Therapeutics, Inc.$63.3M0.25%$32.31$113.51+251.3%
0.3%
NRIXNurix Therapeutics, Inc.$62.5M0.25%$34.91$23.97-31.3%
0.3%
ALLKAllakos Inc.$56.9M0.23%β€”β€”
0.2%
ADCTADC Therapeutics SA$55.7M0.22%$32.99$1.19-96.4%
0.2%
RYTMRhythm Pharmaceuticals, Inc.$53.5M0.21%$21.67$114.17+426.9%
0.2%
HZNPHorizon Therapeutics Public Ltd Co$51.8M0.21%β€”β€”
0.2%

AttivitΓ  Trimestre su Trimestre

Q3 2020 vs. Q2 2020

Nuove Posizioni (8)

TickerEmittenteNozionaleDal Deposito
SGENSeagen Inc.$9.25B
PRLDPrelude Therapeutics Incorporated$304.9M-83.7%
KYMRKymera Therapeutics, Inc.$63.3M+251.3%
NRIXNurix Therapeutics, Inc.$62.5M-31.3%
PACBPacific Biosciences of California, Inc.$32.1M
Invitae Corporation$16.9M
ATHAAthira Pharma, Inc.$16.3M
HRMYHarmony Biosciences Holdings, Inc.$13.6M

Posizioni Chiuse (8)

TickerEmittenteNozionale
SGENXXXXSeattle Genetics, Inc.$8.03B
PRNBPrincipia Biopharma Inc.$94.5M
TCDAQTricida, Inc.$21.6M
AIMTAimmune Therapeutics, Inc.$11.3M
ABEOAbeona Therapeutics Inc.$4.6M
ARYAARYA Sciences Acquisition Corp.$2.4M
MTNBMatinas BioPharma Holdings, Inc.$1.6M
MRKRMarker Therapeutics, Inc.$0.5M

Aumentate (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
REPLReplimune Group, Inc.$4.6M+3918.4%
GBTGlobal Blood Therapeutics, Inc.$47.8M+1858.2%
HZNPHorizon Therapeutics Public Ltd Co$40.7M+233.2%
CBAYCymabay Therapeutics, Inc.$18.2M+113.6%
ALBOAlbireo Pharma, Inc.$8.6M+48.8%
OVIDOvid Therapeutics Inc.$0.0M+28.9%
ONCBeiGene, Ltd.$1.59B+12.9%+3.9%
NLTXNeoleukin Therapeutics, Inc.$-10.5M+12.5%

Ridotte (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
SNSSSunesis Pharmaceuticals, Inc.$-0.1M-90.5%
EVFMEvofem Biosciences, Inc.$-3.0M-69.6%
ARAVAravive, Inc.$-2.5M-68.9%
LPTXLeap Therapeutics, Inc.$-0.9M-42.8%
APLTApplied Therapeutics, Inc.$-1.6M-42.3%
IMMUImmunomedics, Inc.$8.5M-28.0%
NBIXNeurocrine Biosciences, Inc.$-45.5M-25.4%+81.2%
GWPHGW Pharmaceuticals plc$-9.2M-25.0%
← Torna agli Hedge Fund